Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity.
about
Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalitiesInfluenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspectiveThe pandemic influenza A (H1N1) 2009 vaccine does not increase the mortality rate of idiopathic interstitial pneumonia: a matched case-control study.Is Systemic Lupus Erythematosus Associated With a Declined Immunogenicity and Poor Safety of Influenza Vaccination?: A Systematic Review and Meta-Analysis.Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study.Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases.Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus.An audit of influenza and pneumococcal vaccination in rheumatology outpatients.Interleukin-10-producing LAG3+ regulatory T cells are associated with disease activity and abatacept treatment in rheumatoid arthritis.Infection in systemic lupus erythematosus: friend or foe?Vaccinations in patients with immune-mediated inflammatory diseases2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic featuresHigh Affinity Antibodies against Influenza Characterize the Plasmablast Response in SLE Patients After Vaccination.Immunogenicity and Safety of Influenza Vaccination in Systemic Lupus Erythematosus Patients Compared with Healthy Controls: A Meta-Analysis.Is rheumatoid arthritis associated with reduced immunogenicity of the influenza vaccination? A systematic review and meta-analysis.Rituximab-treated patients have a poor response to influenza vaccinationSafety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 yearsVaccine-preventable infections in Systemic Lupus Erythematosus.Vaccination in patients with chronic rheumatic or autoimmune diseases.Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responsesVaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics.Safety of vaccination of patients with systemic lupus erythematosus.Are anti-infectious vaccinations safe and effective in patients with autoimmunity?Vaccination of patients with autoimmune inflammatory rheumatic diseases.Factors affecting immune responses to the influenza vaccine.H1N1 vaccination in Sjögren's syndrome triggers polyclonal B cell activation and promotes autoantibody production.Randomized trial investigating the safety and efficacy of influenza vaccination in patients with antineutrophil cytoplasmic antibody-associated vasculitis.Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients.Infections and systemic lupus erythematosus.The risk of systemic lupus erythematosus associated with vaccines: an international case-control study.Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus.Appropriate response to influenza A (H1N1) virus vaccination in patients with inflammatory bowel disease on maintenance immunomodulator and/or biological therapy.The influence of prebiotic or probiotic supplementation on antibody titers after influenza vaccination: a systematic review and meta-analysis of randomized controlled trials.Autoantibody response to adjuvant and nonadjuvant H1N1 vaccination in systemic lupus erythematosus.Does Vitamin D Deficiency Affect the Immunogenic Responses to Influenza Vaccination? A Systematic Review and Meta-Analysis.
P2860
Q26796420-2A33A491-449F-4092-A759-4B4FB47B3760Q28740919-2B4131C5-6B28-4807-80B5-12F760ACED49Q30359671-1EE86724-AB2F-4703-9DFB-75138E59EFA9Q30388063-4C99795B-24A4-4716-8AAC-FBD518F86144Q30400508-10932CFC-E54B-4B65-9C68-919DBD321C6FQ30401020-61D3A1F3-0E26-46BB-A806-75557BCFF9D9Q30405609-3206A65D-8300-413F-998E-9349D38DBA7CQ33289919-B0AC0147-5DDF-4605-B15C-76E0619054FEQ33696751-42FFB08B-9FD8-4FEF-BE95-495E6D6261A1Q33696879-97A2608B-7848-4F3D-A1A3-1726609F19F7Q34117134-761E5FAC-B804-4CBC-969F-0024209CC570Q34390072-25B7B9FB-EE9B-4940-8EEC-596B8FC50999Q35146181-3216315F-16FD-401C-8F02-B278C877C6D3Q35624357-4C345D56-63CE-4807-AFB1-3334861A84B0Q35914564-7DE28E17-9AA4-403A-BDB0-2B2939F69155Q36367842-584A77BC-2608-42F9-982D-A669C69697B7Q36589247-06CF231D-D2E4-4E2F-965E-E60107CF1280Q37115262-DE9CF853-3329-4D39-813E-E03A4D1F21C6Q37135056-30160D6F-E120-429C-A267-1ECA2B57F6D2Q37141193-67E493C4-4C92-457C-B7B0-D53304F8DA58Q37416103-4A2278C0-A15B-4A88-B28B-FF6DF892F327Q37492480-17B0E665-CDFD-4533-B222-DCB3BB509AE9Q37625587-93924B07-7987-4A39-8853-EBC10218E1E1Q37762551-2EE716BD-EC31-400E-AF4E-81EDA264E17BQ38285275-6CB49600-C9A8-4AE2-AC18-FA3FB25D8D79Q39375320-16C4BBBC-D157-4D01-BA9C-40BFA90E9F07Q41912227-8EBDECB9-E408-46B1-AEBB-32C7B47267FFQ42172279-37A81451-E1E2-491B-A76F-C0BEE5BA2C0AQ42215038-E8A18133-309B-4837-B94B-4D38692E0933Q42220143-29849B46-7C31-45FD-A448-710DEE12A063Q44548276-654CC31F-1363-48BE-9F0B-E4EA3D7EF536Q44865311-1ABCBB04-D258-4D99-B2FD-DC9454D77E70Q45369289-0E8A27AE-32D5-4B83-9914-4EE671819B62Q49340262-8CF5BA2D-BB74-4088-9EDE-D5B7509DD7AFQ53143090-B809B3F1-807F-4F68-A4F6-F0B7C9F2DF9CQ54247359-F26D7372-CBE1-46CA-90EF-5D32B1BBC37F
P2860
Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Influenza vaccine administrati ...... is. Safety and immunogenicity.
@en
Influenza vaccine administrati ...... is. Safety and immunogenicity.
@nl
type
label
Influenza vaccine administrati ...... is. Safety and immunogenicity.
@en
Influenza vaccine administrati ...... is. Safety and immunogenicity.
@nl
prefLabel
Influenza vaccine administrati ...... is. Safety and immunogenicity.
@en
Influenza vaccine administrati ...... is. Safety and immunogenicity.
@nl
P2093
P1433
P1476
Influenza vaccine administrati ...... tis. Safety and immunogenicity
@en
P2093
Campitelli L
Cardelli P
D'Amelio R
Donatelli I
P304
P356
10.1016/J.VACCINE.2006.01.028
P407
P577
2006-01-23T00:00:00Z